Ciara Curtin

Atlanta

Senior Editor at GenomeWeb

I am a science writer and editor. I also like food, running, and yoga. All views expressed here are my own.

Featured in: Favicon

genomeweb.com Favicon

scientificamerican.com Favicon

modernhealthcare.com Favicon

spectrumnews.org Favicon

360dx.com

precisiononcologynews.com Favicon

precisionmedicineonline.com

Articles

Dyne Reports on Response Predictive Biomarkers for Neurodegenerative Disorder Genetic Medicine

1 month ago | precisionmedicineonline.com | Ciara Curtin

NEW ORLEANS – Certain markers of gene-splicing correction may predict functional improvements among myotonic dystrophy type 1 (DM1) patients treated with Dyne Therapeutics' investigational antisense oligonucleotide (ASO), according to early results presented at the American Society of Gene & Cell Therapy's annual meeting. Dyne is evaluating the ASO, dubbed DYNE-101, in about 104 DM1 patients in the Phase I/II ACHIEVE clinical trial.
Sarepta's Elevidys May Benefit Older Duchenne Patients, ASGCT Data Show

1 month ago | precisionmedicineonline.com | Ciara Curtin

NEW ORLEANS – Older Duchenne muscular dystrophy patients treated with Sarepta Therapeutics' Elevidys (delandistrogene moxeparvovec) showed evidence of slowing disease progression or disease stabilization, according to data from the Phase III EMBARK trial presented at the American Society of Gene and Cell Therapy's annual meeting.
ASGCT25: HuidaGene, Lingyi Biotechnology, UCSD, Reforgene Medicine, iECURE, and More

1 month ago | precisionmedicineonline.com | Jessica Cohen |Ciara Curtin

NEW ORLEANS – At the American Society of Gene & Cell Therapy's annual meeting held here this week, researchers and drugmakers presented data on their products for treating various rare and genetic diseases. Below are brief reports on presentations from Wednesday and Thursday.
Personalized Base Editing Treats Infant With Rare Urea Cycle Disorder

1 month ago | precisionmedicineonline.com | Ciara Curtin

NEW ORLEANS – Investigators developed a personalized base-editing therapy for an infant with a urea cycle disorder and treated him with the bespoke therapy within a few months of his birth, according to data presented Thursday by the University of Pennsylvania's Kiran Musunuru at the American Society of Gene & Cell Therapy meeting.
Initiatives to Develop Cell, Gene Therapies Locally in Low- and Middle-Income Countries Gain Traction

1 month ago | precisionmedicineonline.com | Ciara Curtin

NEW YORK – Cell and gene therapies have the potential to be one-time treatments for a range of diseases from lymphoma and leukemia to sickle cell and HIV. Even though many of these diseases disproportionately affect people living in low- and middle-income countries, patients have limited access to these advanced treatments in part due to their high cost.
AstraZeneca Anticipates Limited Effect of Tariffs, Reports Q1 Oncology Revenue Growth

2 months ago | precisionmedicineonline.com | Ciara Curtin

NEW YORK – AstraZeneca executives said the firm is well positioned to handle any tariffs enacted by the US on pharmaceutical imports. According to AstraZeneca CEO Pascal Soriot, most of the firm's drugs that are sold in the US are manufactured domestically and only a small number are imported from Europe. The Trump Administration has threatened to impose a 25 percent tariff on pharmaceutical imports.
Tenaya's Hypertrophic Cardiomyopathy Gene Therapy Well Tolerated in Interim MyPEAK-1 Trial Data

2 months ago | precisionmedicineonline.com | Ciara Curtin

CHICAGO – Treatment with Tenaya Therapeutics' investigational gene therapy, TN-201, for MYBPC3-associated hypertrophic cardiomyopathy (HCM) was well tolerated and led to symptom improvement, according to interim clinical trial data. Milind Desai, director of the Hypertrophic Cardiomyopathy Center at Cleveland Clinic and an investigator on the trial, presented the first-in-human data from the Phase Ib/II MyPEAK-1 trial at the American College of Cardiology's annual meeting on Monday.
AI Analysis of Routine Cardiac Tests May Serve as Screen to Identify Undiagnosed ATTR-CM

Mar 30, 2025 | precisionmedicineonline.com | Ciara Curtin

CHICAGO – Artificial intelligence-fueled analysis of routine cardiac testing may uncover otherwise overlooked cases of transthyretin cardiac amyloidosis (ATTR-CM), according to a new analysis presented Saturday at the American College of Cardiology's annual meeting. ATTR-CM is a severe and progressive disease marked by the accumulation of abnormal transthyretin (TTR) proteins in the heart and leads to heart failure.
Plasma Proteomic Profiling Predicts Prognosis, Response to Treatment in Some ATTR-CM Patients

Mar 30, 2025 | precisionmedicineonline.com | Ciara Curtin

CHICAGO – Signals from the plasma proteome may help identify which transthyretin cardiac amyloidosis (ATTR-CM) patients will respond better to therapy, early-stage research presented Saturday at the American College of Cardiology's annual meeting suggests.
Precision Medicine Supporters Worry About NIH Indirect Rate Cut's Impact on Advances, Workforce

Feb 12, 2025 | precisionmedicineonline.com | Jessica Cohen |Alison Kanski |Catherine Shaffer |Ciara Curtin

NEW YORK – The life sciences sector is still reeling from the announcement last week that the US National Institutes of Health intends to limit indirect costs for research grants to15 percent. The policy has those in the precision medicine space particularly worried about the effect this may have on the bourgeoning field's ability to continue to develop advanced treatments like cell and gene therapies and maintain an expert workforce.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers: 136
Tweets: 557
DMs Open: No

Ciara Curtin @ciarzc

4 Nov 24

RT @ATLUTD: THAT'S HOW WE DO IT IN ATLANTA. #UniteThe404 https://t.co/6JrzS5Z4UZ

Ciara Curtin @ciarzc

31 Oct 23

RT @JessicaKimCohen: A spate of consortiums, non-profits & research efforts are cropping up to build momentum for antisense oligonucleotide…

Ciara Curtin @ciarzc

22 Oct 23

RT @Ch_Hops: Lots of #precisiononcology #cancertreatment news coming out of Madrid this weekend. Here's a little thread of my indefatigable…

Ciara Curtin

Articles

Dyne Reports on Response Predictive Biomarkers for Neurodegenerative Disorder Genetic Medicine

Sarepta's Elevidys May Benefit Older Duchenne Patients, ASGCT Data Show

ASGCT25: HuidaGene, Lingyi Biotechnology, UCSD, Reforgene Medicine, iECURE, and More

Personalized Base Editing Treats Infant With Rare Urea Cycle Disorder

Initiatives to Develop Cell, Gene Therapies Locally in Low- and Middle-Income Countries Gain Traction

AstraZeneca Anticipates Limited Effect of Tariffs, Reports Q1 Oncology Revenue Growth

Tenaya's Hypertrophic Cardiomyopathy Gene Therapy Well Tolerated in Interim MyPEAK-1 Trial Data

AI Analysis of Routine Cardiac Tests May Serve as Screen to Identify Undiagnosed ATTR-CM

Plasma Proteomic Profiling Predicts Prognosis, Response to Treatment in Some ATTR-CM Patients

Precision Medicine Supporters Worry About NIH Indirect Rate Cut's Impact on Advances, Workforce

Contact details

Emails

Socials & Sites

X (formerly Twitter)